BRAF and neoplasm: In line with the current advances in tumour immunology, our data may suggest that RAS-like PTC with FAL1 and ECM1 upregulation proceeds from carcinogenesis to aggressive PTC by an immunological mechanism compared to classical BRAF-like PTC.